Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SORT1 | Q99523 | 1/20 | 0.50 |
| ▸ | JUN | P05412 | 1/20 | 0.49 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.49 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.49 |
| ▸ | RELA | Q04206 | 1/20 | 0.49 |
| ▸ | P2RX1 | P51575 | 1/20 | 0.46 |
| ▸ | TRPV1 | Q8NER1 | 3/20 | 0.46 |
| ▸ | LCK | P06239 | 1/20 | 0.46 |
| ▸ | BTK | Q06187 | 1/20 | 0.46 |
| ▸ | NTRK1 | P04629 | 2/20 | 0.45 |
| ▸ | MCHR1 | Q99705 | 1/20 | 0.45 |
| ▸ | TEK | Q02763 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31339978 | 0.90 | BTK (0.48) | SORT1TRPV1LCKBTKMCHR1 | |
| SCHEMBL31340012 | 0.87 | KDM4E (0.46) | SORT1TRPV1LCKBTK | |
| SCHEMBL31339954 | 0.86 | VNN1 (0.45) | SORT1TRPV1MCHR1 | |
| SCHEMBL31339994 | 0.85 | TRPV1 (0.46) | SORT1TRPV1LCKMCHR1TEK | |
| SCHEMBL31339981 | 0.85 | ALDH1A1 (0.43) | SORT1P2RX1TRPV1MCHR1 | |
| SCHEMBL31339987 | 0.84 | TRPV1 (0.57) | TRPV1TEK | |
| SCHEMBL31340005 | 0.83 | TRPV1 (0.46) | TRPV1 | |
| SCHEMBL31339962 | 0.83 | LCK (0.59) | TRPV1LCKBTKTEK | |
| SCHEMBL34462417 | 0.82 | TRPV1 (0.47) | TRPV1 | |
| SCHEMBL31340007 | 0.81 | PTGS1 (0.54) | SORT1TRPV1BTK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260124202-A1 | CD97 AND GSDME INTERACTION INHIBITOR HAVING ANTI-TUMOR ACTIVITY AND APPLICATION THEREOF | JILIN UNIVERSITY (CN) | 2026-05-07 | — | — | US | disclosed |
| EP-4725485-A1 | CD97 AND GSDME INTERACTION INHIBITOR HAVING ANTI-TUMOR ACTIVITY AND APPLICATION THEREOF | Jilin University (CN) | 2026-04-15 | — | — | EP | disclosed |
| CN-119285557-A | CD97 and GSDME interaction inhibitor with anti-tumor activity and application thereof | 吉林大学 | 2025-01-10 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260124202-A1 | CD97 AND GSDME INTERACTION INHIBITOR HAVING ANTI-TUMOR ACTIVITY AND APPLICATION THEREOF | GZMB, CD74, GSDMD | SORT1 4391/4885JUN 2756/4885NFKB1 2188/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.